Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients.

Standard

Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients. / Haubitz, M; Kliem, V; Koch, K M; Nashan, Björn; Schlitt, H J; Pichlmayr, R; Brunkhorst, R.

in: TRANSPLANTATION, Jahrgang 63, Nr. 9, 9, 1997, S. 1251-1257.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Haubitz, M, Kliem, V, Koch, KM, Nashan, B, Schlitt, HJ, Pichlmayr, R & Brunkhorst, R 1997, 'Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients.', TRANSPLANTATION, Jg. 63, Nr. 9, 9, S. 1251-1257. <http://www.ncbi.nlm.nih.gov/pubmed/9158017?dopt=Citation>

APA

Haubitz, M., Kliem, V., Koch, K. M., Nashan, B., Schlitt, H. J., Pichlmayr, R., & Brunkhorst, R. (1997). Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients. TRANSPLANTATION, 63(9), 1251-1257. [9]. http://www.ncbi.nlm.nih.gov/pubmed/9158017?dopt=Citation

Vancouver

Haubitz M, Kliem V, Koch KM, Nashan B, Schlitt HJ, Pichlmayr R et al. Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients. TRANSPLANTATION. 1997;63(9):1251-1257. 9.

Bibtex

@article{4e55c1ceff7141f6b5075f8668929aa8,
title = "Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients.",
abstract = "BACKGROUND: In patients with autoimmune diseases such as vasculitis or systemic lupus erythematosus (SLE), end-stage renal disease develops in a high percentage of patients, and kidney transplantation has become a therapeutic option. However, only limited data about the prognosis and outcome after kidney transplantation are available. METHODS: Long-term graft survival and graft function of renal transplant recipients with SLE, Wegener's granulomatosis, microscopic polyangiitis, Goodpasture's syndrome, and Henoch-Schonlein purpura were evaluated in a single center. In addition, the incidence of renal and extrarenal relapses and the impact of the immunosuppressive therapy on the course of the autoimmune disease were studied. RESULTS: Renal transplant recipients with autoimmune diseases such as vasculitis and SLE had a patient survival rate (94% after 5 years) and a graft survival rate (65% after 5 years) comparable to those of patients with other causes of end-stage renal disease (patient survival 88% and graft survival 71% after 5 years). Graft losses due to the underlying disease were rare. Extrarenal relapses occurred in three patients with Wegener's granulomatosis, one patient with microscopic polyangiitis, and three patients with SLE, but were less frequent compared with the period with chronic dialysis therapy. Autoantibody levels in patients with SLE, Wegener's granulomatosis, or microscopic polyangiitis did not seem to influence the outcome. CONCLUSIONS: Renal transplantation should be offered to patients with autoimmune diseases. Follow-up should include the short-term control of renal and extrarenal disease activity.",
author = "M Haubitz and V Kliem and Koch, {K M} and Bj{\"o}rn Nashan and Schlitt, {H J} and R Pichlmayr and R Brunkhorst",
year = "1997",
language = "Deutsch",
volume = "63",
pages = "1251--1257",
journal = "TRANSPLANTATION",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

RIS

TY - JOUR

T1 - Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients.

AU - Haubitz, M

AU - Kliem, V

AU - Koch, K M

AU - Nashan, Björn

AU - Schlitt, H J

AU - Pichlmayr, R

AU - Brunkhorst, R

PY - 1997

Y1 - 1997

N2 - BACKGROUND: In patients with autoimmune diseases such as vasculitis or systemic lupus erythematosus (SLE), end-stage renal disease develops in a high percentage of patients, and kidney transplantation has become a therapeutic option. However, only limited data about the prognosis and outcome after kidney transplantation are available. METHODS: Long-term graft survival and graft function of renal transplant recipients with SLE, Wegener's granulomatosis, microscopic polyangiitis, Goodpasture's syndrome, and Henoch-Schonlein purpura were evaluated in a single center. In addition, the incidence of renal and extrarenal relapses and the impact of the immunosuppressive therapy on the course of the autoimmune disease were studied. RESULTS: Renal transplant recipients with autoimmune diseases such as vasculitis and SLE had a patient survival rate (94% after 5 years) and a graft survival rate (65% after 5 years) comparable to those of patients with other causes of end-stage renal disease (patient survival 88% and graft survival 71% after 5 years). Graft losses due to the underlying disease were rare. Extrarenal relapses occurred in three patients with Wegener's granulomatosis, one patient with microscopic polyangiitis, and three patients with SLE, but were less frequent compared with the period with chronic dialysis therapy. Autoantibody levels in patients with SLE, Wegener's granulomatosis, or microscopic polyangiitis did not seem to influence the outcome. CONCLUSIONS: Renal transplantation should be offered to patients with autoimmune diseases. Follow-up should include the short-term control of renal and extrarenal disease activity.

AB - BACKGROUND: In patients with autoimmune diseases such as vasculitis or systemic lupus erythematosus (SLE), end-stage renal disease develops in a high percentage of patients, and kidney transplantation has become a therapeutic option. However, only limited data about the prognosis and outcome after kidney transplantation are available. METHODS: Long-term graft survival and graft function of renal transplant recipients with SLE, Wegener's granulomatosis, microscopic polyangiitis, Goodpasture's syndrome, and Henoch-Schonlein purpura were evaluated in a single center. In addition, the incidence of renal and extrarenal relapses and the impact of the immunosuppressive therapy on the course of the autoimmune disease were studied. RESULTS: Renal transplant recipients with autoimmune diseases such as vasculitis and SLE had a patient survival rate (94% after 5 years) and a graft survival rate (65% after 5 years) comparable to those of patients with other causes of end-stage renal disease (patient survival 88% and graft survival 71% after 5 years). Graft losses due to the underlying disease were rare. Extrarenal relapses occurred in three patients with Wegener's granulomatosis, one patient with microscopic polyangiitis, and three patients with SLE, but were less frequent compared with the period with chronic dialysis therapy. Autoantibody levels in patients with SLE, Wegener's granulomatosis, or microscopic polyangiitis did not seem to influence the outcome. CONCLUSIONS: Renal transplantation should be offered to patients with autoimmune diseases. Follow-up should include the short-term control of renal and extrarenal disease activity.

M3 - SCORING: Zeitschriftenaufsatz

VL - 63

SP - 1251

EP - 1257

JO - TRANSPLANTATION

JF - TRANSPLANTATION

SN - 0041-1337

IS - 9

M1 - 9

ER -